Data Characteristics

Data collection included demographic information [gender, age, height, weight, body mass index (BMI)] and clinical data, including the following: NAFLD, hypertension, diabetes or impaired fasting glucose (IFG), hepatitis B surface antigen (HBsAg), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), triglyceride (TG), platelet (PLT), albumin (ALB) and the following tumor markers: carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and alpha-fetoprotein (AFP). Tumor characteristic which based on the guideline of the American Joint Committee on Cancer staging, with detailed descriptions on each patient's pathology report, including primary tumor site, tumor size, tumor type (protuberant, ulcerative, infiltrative), differentiation (well, moderate, poor), tumor (T) status, lymph node (N) status, TNM stage, vascular invasion, nerve invasion, and KRAS, NRAS, BRAF mutation status. The original data for all patients in this study were shown in Supplementary Data Sheet 1.